Analyst Price Target is $47.50
▲ +46.15% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Xencor in the last 3 months. The average price target is $47.50, with a high forecast of $58.00 and a low forecast of $36.00. The average price target represents a 46.15% upside from the last price of $32.50.
Current Consensus is
The current consensus among 10 contributing investment analysts is to buy stock in Xencor. This rating has held steady since February 2021, when it changed from a Hold consensus rating.
Xencor, Inc. is biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.